At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Study of Subcutaneous Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for Untreated Indolent B-Cell Non-Hodgkin Lymphoma
In Brief
A Phase 2 clinical trial evaluating Mosunetuzumab, Obinutuzumab, and 7 other interventions for Non-Hodgkin Lymphoma and 7 related conditions. Completed, enrolled 42 participants across 1 site.
Detailed Summary
This phase II trial tests the effects of mosunetuzumab with or without polatuzumab vedotin and obinutuzumab for the treatment of patients with indolent B-cell non-Hodgkin lymphoma. Mosunetuzumab and obinutuzumab are monoclonal antibodies that may interfere with the ability of cancer cells to grow and spread. Polatuzumab vedotin is a monoclonal antibody, called polatuzumab, linked to a chemotherapy drug, called vedotin. Polatuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as CD79b receptors, and delivers vedotin to kill them. Giving mosunetuzumab with polatuzumab vedotin and obinutuzumab may work better in treating patients with untreated indolent B-cell non-Hodgkin lymphoma.
Study Details
Timeline
Interventions
Given SC
Given IV
Given IV
Undergo FDG-PET and FDG-PET/CT
Undergo CT and FDG-PET/CT
Undergo PET/CT and FDG-PET/CT
Undergo bone marrow biopsy
Undergo bone marrow aspiration
Undergo blood sample collection